<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300742</url>
  </required_header>
  <id_info>
    <org_study_id>12069</org_study_id>
    <nct_id>NCT00300742</nct_id>
  </id_info>
  <brief_title>Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals</brief_title>
  <official_title>Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individual</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the feasibility of using topiramate to reduce binge&#xD;
      eating and drinking episodes in alcohol dependent individuals with comorbid binge eating&#xD;
      disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research has shown an alarming coincidence of binge eaters also reporting serious alcohol&#xD;
      abuse. Evidence has shown this population to have higher rates of psychiatric comorbidity,&#xD;
      higher caloric intakes during meals, higher rates of tobacco use, more frequent binge&#xD;
      episodes, and an earlier age of onset for binge eating and alcohol abuse. It is believed that&#xD;
      topiramate may reduce binge eating and has been found helpful in reducing the cravings&#xD;
      associated with alcohol consumption.&#xD;
&#xD;
      This study is to test the feasibility of administering topiramate to individuals with alcohol&#xD;
      dependence and binge eating disorder. This will involve determining the adequacy of the&#xD;
      amount of assessment and scheduled visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compliance With Study Requirements: Attendance at Treatment Sessions</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Drinks Per Day at Baseline vs. Visit 12</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Mean drinks per day at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Days Abstinent Per Week at Baseline vs. Visit 12</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Mean percent days abstinent per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Binge Eating Episodes Per Week at Baseline vs. Visit 12</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Mean binge eating episodes per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance With Study Requirements: Topiramate Level</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Number of subjects who escalated to the maximum dose of 300 mg of topiramate/day</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Binge Eating</condition>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Topiramate Other Name for Topiramate: Topamax</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Topiramate up to 300 mg per day.</description>
    <arm_group_label>Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females that have given written informed consent.&#xD;
&#xD;
          -  Good physical health as confirmed by a complete physical examination, vital signs&#xD;
             including an EKG within normal limits, laboratory screening tests within acceptable&#xD;
             parameters (see exclusion criteria), as well as a baseline psychiatric history&#xD;
&#xD;
          -  Diagnosis of alcohol dependence and binge eating disorder.&#xD;
&#xD;
          -  Subjects must have 3 or more binge days per week in the 2-week period prior to Screen.&#xD;
&#xD;
          -  Subjects may have uncomplicated and well-controlled Type II diabetes and/or&#xD;
             hypertension that has been well controlled by diet and/or oral agent therapy for at&#xD;
             least 3 months prior to screen.&#xD;
&#xD;
          -  Provide evidence of stable residence in the last month.&#xD;
&#xD;
          -  The pregnancy test for females at intake must be negative. The female patients must&#xD;
             either be sterile, post menopausal, or practicing an acceptable form of contraception.&#xD;
&#xD;
          -  Literate in English and able to read, understand, and complete the ratings scales and&#xD;
             questionnaires accurately, follow instructions, and make use of the behavioral&#xD;
             treatment.&#xD;
&#xD;
          -  Subjects must have signed an informed consent document indicating that they understand&#xD;
             the purpose of and procedures required for the study and are willing to participate in&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any current DSM-IV psychiatric diagnosis other than alcohol, nicotine dependence or&#xD;
             binge eating disorder&#xD;
&#xD;
          -  Subjects who have begun to receive formal psychotherapy (cognitive-behavioral therapy,&#xD;
             interpersonal therapy, dietary behavioral therapy*, or self-guided&#xD;
             cognitive-behavioral) for binge-eating disorder or any other psychiatric disorder&#xD;
             within 30 days prior to Screen. Subjects who have been engaged in formal psychotherapy&#xD;
             for a longer period of time and plan to maintain therapy will be judged on a&#xD;
             case-by-case basis.&#xD;
&#xD;
               -  Formal dietary behavioral therapy applies to therapy where the subject is&#xD;
                  diagnosed with an eating disorder and/or the health case provider is billing for&#xD;
                  costs of therapy (will be considered on a case-by-case basis if started within 30&#xD;
                  days of Screen. Subjects engaged in dietary for obesity only (e.g., Jenny Craig,&#xD;
                  Weight Watchers, Overeater's Anonymous) should discontinue therapy prior to study&#xD;
                  entry (no washout applies).&#xD;
&#xD;
          -  Clinically significant laboratory screening test.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease on a 12 lead EKG.&#xD;
&#xD;
          -  Symptomatic coronary artery disease or peripheral vascular disease.&#xD;
&#xD;
          -  Malignancy or history of malignancy within the past 5 years (except basal cell&#xD;
             carcinoma).&#xD;
&#xD;
          -  Clinically significant neurological disease.&#xD;
&#xD;
          -  Clinically significant renal disease or impaired renal function as defined by subjects&#xD;
             with an estimated creatinine clearance of less than 60 mL/min.&#xD;
&#xD;
          -  Severe withdrawal symptoms which in the physicians' opinion requires inpatient&#xD;
             treatment or severe or life-threatening adverse reactions to medications either in the&#xD;
             past or during this clinical trial.&#xD;
&#xD;
          -  Female patients who are pregnant, lactating, or not adhering to an acceptable form of&#xD;
             contraception at any time during the study.&#xD;
&#xD;
          -  Members of the same household.&#xD;
&#xD;
          -  History of severe hypersensitivity to any medication or environmental allergens.&#xD;
&#xD;
          -  Subjects with prior non-response to topiramate for the treatment of binge-eating and&#xD;
             or alcohol disorder following an adequate trial of this medication&#xD;
&#xD;
          -  Subjects who have been previously treated with topiramate for any reason and&#xD;
             discontinued treatment due to an adverse event or due to a hypersensitivity reaction&#xD;
             to topiramate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nassima Ait-Daoud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia, Department of Psychiatric Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UVA CARE</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UVA CARE Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>March 7, 2006</study_first_submitted>
  <study_first_submitted_qc>March 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2006</study_first_posted>
  <results_first_submitted>March 31, 2017</results_first_submitted>
  <results_first_submitted_qc>March 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2017</results_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Nassima Ait-Daoud Tiouririne</investigator_full_name>
    <investigator_title>Associate Professor, Director of UVA Center for Addiction Research and Education</investigator_title>
  </responsible_party>
  <keyword>drinking</keyword>
  <keyword>eating</keyword>
  <keyword>obesity</keyword>
  <keyword>alcohol</keyword>
  <keyword>binge eating</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in Charlottesville and Richmond between September 2006 to February 2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Topiramate/BBCET</title>
          <description>Escalating dose of up to 300 mg/day of Topiramate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topiramate/BBCET</title>
          <description>Escalating dose of up to 300 mg/day of Topiramate</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="10.46422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Compliance With Study Requirements: Attendance at Treatment Sessions</title>
        <time_frame>up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate/BBCET</title>
            <description>Patients receiving an escalating dose of up to 300 mg/day of Topiramate, plus BBCET (Brief Behavioral Compliance Enhancement Treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With Study Requirements: Attendance at Treatment Sessions</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects completed through Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects completed through Visit 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Drinks Per Day at Baseline vs. Visit 12</title>
        <description>Mean drinks per day at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate/BBCET</title>
            <description>Escalating dose of up to 300 mg/day of Topiramate, plus BBCET (Brief Behavioral Compliance Enhancement Treatment)at 12 weekly visits following the initial baseline and randomization visits</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Drinks Per Day at Baseline vs. Visit 12</title>
          <description>Mean drinks per day at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
          <population>Per protocol</population>
          <units>Drinks/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean drinks per day at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.95" spread="13.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean drinks per day at Visit 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Days Abstinent Per Week at Baseline vs. Visit 12</title>
        <description>Mean percent days abstinent per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate/BBCET</title>
            <description>Escalating dose of up to 300 mg/day of Topiramate, plus BBCET (Brief Behavioral Compliance Enhancement Treatment)at 12 weekly visits following the initial baseline and randomization visits</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Days Abstinent Per Week at Baseline vs. Visit 12</title>
          <description>Mean percent days abstinent per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
          <population>Per protocol</population>
          <units>Mean percent days abstinent per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean percent days abstinent per week at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="21.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean percent days abstinent per week at Visit 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Binge Eating Episodes Per Week at Baseline vs. Visit 12</title>
        <description>Mean binge eating episodes per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate/BBCET</title>
            <description>Escalating dose of up to 300 mg/day of Topiramate, plus BBCET (Brief Behavioral Compliance Enhancement Treatment)at 12 weekly visits following the initial baseline and randomization visits</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Binge Eating Episodes Per Week at Baseline vs. Visit 12</title>
          <description>Mean binge eating episodes per week at baseline vs. Visit 12 measured by self report on timeline follow-back (TLFB) calendars in conjunction with the subject's daily diary</description>
          <population>Per protocol</population>
          <units>Binge eating episodes/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean weekly binge eating episodes at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean weekly binge eating episodes at Visit 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Compliance With Study Requirements: Topiramate Level</title>
        <description>Number of subjects who escalated to the maximum dose of 300 mg of topiramate/day</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>This is the number of participants who reached the dose of 300 mg of topiramate</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate/BBCET</title>
            <description>Patients receiving an escalating dose of up to 300 mg/day of Topiramate, plus BBCET (Brief Behavioral Compliance Enhancement Treatment)</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With Study Requirements: Topiramate Level</title>
          <description>Number of subjects who escalated to the maximum dose of 300 mg of topiramate/day</description>
          <population>This is the number of participants who reached the dose of 300 mg of topiramate</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Topiramate/BBCET</title>
          <description>Escalating dose of up to 300 mg/day of Topiramate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nassima Ait-Daoud</name_or_title>
      <organization>UVA Center for Addiction Research and Education</organization>
      <phone>434-243-0541</phone>
      <email>uvacare@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

